share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5:募資說明書
美股SEC公告 ·  05/02 07:58

Moomoo AI 已提取核心訊息

Allarity Therapeutics Inc. has filed a new prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $10 million to $18 million. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company plans to offer and sell its common stock through Ascendiant Capital Markets, LLC, acting as the Sales Agent, under the terms of the At-The-Market Issuance Sales Agreement. As of March 6, 2024, the aggregate market value of Allarity's common stock held by non-affiliates was approximately $55.1 million, with the company having already sold $12.9 million worth of stock in the past 12 months. The company is eligible to sell an additional $5.4 million of common stock, ensuring that the total...Show More
Allarity Therapeutics Inc. has filed a new prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $10 million to $18 million. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company plans to offer and sell its common stock through Ascendiant Capital Markets, LLC, acting as the Sales Agent, under the terms of the At-The-Market Issuance Sales Agreement. As of March 6, 2024, the aggregate market value of Allarity's common stock held by non-affiliates was approximately $55.1 million, with the company having already sold $12.9 million worth of stock in the past 12 months. The company is eligible to sell an additional $5.4 million of common stock, ensuring that the total does not exceed one-third of the aggregate market value of the stock held by non-affiliates within any 12-month period, as per General Instruction I.B.6 of Form S-3. The company cautions that investing in its common stock involves a high degree of risk, as detailed in the risk factors section of the prospectus supplement dated March 19, 2024.
Allarity Therapeutics Inc.已於2024年5月2日提交了新的招股說明書補充文件,將其普通股的最高總髮行價從1000萬美元提高到1,800萬美元。本文件修訂了先前於2023年11月29日發佈的招股說明書和2024年3月19日的招股說明書補充文件。根據市場發行銷售協議的條款,該公司計劃通過作爲銷售代理的Ascendiant Capital Markets, LLC發行和出售其普通股。截至2024年3月6日,非關聯公司持有的Allarity普通股的總市值約爲5,510萬美元,該公司在過去12個月中已經出售了價值1,290萬美元的股票。根據S-3表格I.B.6號一般指令,該公司有資格再出售540萬美元的普通股,確保在任何12個月期限內總額不超過非關聯公司持有的股票總市值的三分之一。該公司警告說,投資普通股涉及高風險,如2024年3月19日招股說明書補充文件中的風險因素部分所詳述。
Allarity Therapeutics Inc.已於2024年5月2日提交了新的招股說明書補充文件,將其普通股的最高總髮行價從1000萬美元提高到1,800萬美元。本文件修訂了先前於2023年11月29日發佈的招股說明書和2024年3月19日的招股說明書補充文件。根據市場發行銷售協議的條款,該公司計劃通過作爲銷售代理的Ascendiant Capital Markets, LLC發行和出售其普通股。截至2024年3月6日,非關聯公司持有的Allarity普通股的總市值約爲5,510萬美元,該公司在過去12個月中已經出售了價值1,290萬美元的股票。根據S-3表格I.B.6號一般指令,該公司有資格再出售540萬美元的普通股,確保在任何12個月期限內總額不超過非關聯公司持有的股票總市值的三分之一。該公司警告說,投資普通股涉及高風險,如2024年3月19日招股說明書補充文件中的風險因素部分所詳述。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息